Healthcare Finance: Celgene, AMAG, Takeda Present Hematology Data
Several key presentations will be made at the American Society of Hematology (ASH) annual meeting in Atlanta, Georgia on Dec. 8-11.
On Dec. 11, Celgene will present progression free survival (PFS) and overall survival (OS) data from the MM-003 study, a pivotal Phase III trial that tested pomalidomide in refractory resistant multiple myeloma. The drug is an immunomodulator (IMiD).
Click here to see full sample Page 1.